;PMID: 8781507
;source_file_1919.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..43] = [t:0..43]
;1)sentence:[e:49..102] = [t:49..102]
;2)section:[e:106..152] = [t:106..152]
;3)section:[e:156..233] = [t:156..233]
;4)sentence:[e:237..387] = [t:237..387]
;5)sentence:[e:388..667] = [t:388..667]
;6)sentence:[e:668..756] = [t:668..756]
;7)sentence:[e:757..807] = [t:757..807]
;8)sentence:[e:808..1014] = [t:808..1014]
;9)sentence:[e:1015..1180] = [t:1015..1180]
;10)sentence:[e:1181..1345] = [t:1181..1345]
;11)sentence:[e:1346..1436] = [t:1346..1436]
;12)section:[e:1440..1484] = [t:1440..1484]

;section 0 Span:0..43
;Biochem Pharmacol. 1996 Sep 27;52(6):885-9.
(SEC
  (FRAG (NNP:[0..7] Biochem) (NNP:[8..17] Pharmacol) (.:[17..18] .)
        (``:[19..23] 1996) (NNP:[24..27] Sep) (CD:[28..34] 27;52-LRB-)
        (CD:[34..35] 6) (-RRB-:[35..36] -RRB-) (::[36..37] :) (CD:[37..39] 88)
        (CD:[39..40] 5) (HYPH:[40..41] -) (CD:[41..43] 9.)))

;sentence 1 Span:49..102
;Interaction of nonylphenol and hepatic CYP1A in rats.
;[64..75]:substance:"nonylphenol"
;[88..93]:cyp450:"CYP1A"
(SENT
  (NP-HLN
    (NP (NN:[49..60] Interaction))
    (PP (IN:[61..63] of)
      (NP
        (NP (NN:[64..75] nonylphenol))
        (CC:[76..79] and)
        (NP (JJ:[80..87] hepatic) (NN:[88..93] CYP1A))))
    (PP-LOC (IN:[94..96] in)
      (NP (NNS:[97..101] rats)))
    (.:[101..102] .)))

;section 2 Span:106..152
;Lee PC, Patra SC, Stelloh CT, Lee W, Struve M.
(SEC
  (FRAG (NNP:[106..109] Lee) (NNP:[110..112] PC) (,:[112..113] ,)
        (NNP:[114..119] Patra) (NNP:[120..122] SC) (,:[122..123] ,)
        (NNP:[124..131] Stelloh) (NNP:[132..134] CT) (,:[134..135] ,)
        (NNP:[136..139] Lee) (NNP:[140..141] W) (,:[141..142] ,)
        (NNP:[143..149] Struve) (NNP:[150..152] M.)))

;section 3 Span:156..233
;Department of Pediatrics, Medical College of Wisconsin, Milwaukee 53226,
;USA.
(SEC
  (FRAG (NNP:[156..166] Department) (IN:[167..169] of)
        (NNP:[170..180] Pediatrics) (,:[180..181] ,) (NNP:[182..189] Medical)
        (NNP:[190..197] College) (IN:[198..200] of) (NNP:[201..210] Wisconsin)
        (,:[210..211] ,) (NNP:[212..221] Milwaukee) (CD:[222..227] 53226)
        (,:[227..228] ,) (NNP:[229..232] USA) (.:[232..233] .)))

;sentence 4 Span:237..387
;Both estradiol and nonylphenol (NP) inhibited hepatic microsomal 
;7-ethoxyresorufin O-deethylase (EROD) activity of beta-naphthoflavone-treated
; rats.
;[242..251]:substance:"estradiol"
;[256..267]:substance:"nonylphenol"
;[269..271]:substance:"NP"
;[303..333]:cyp450:"7-ethoxyresorufin O-deethylase"
;[335..339]:cyp450:"EROD"
;[353..372]:substance:"beta-naphthoflavone"
(SENT
  (S
    (NP-SBJ (CC:[237..241] Both)
      (NP (NN:[242..251] estradiol))
      (CC:[252..255] and)
      (NP
        (NP (NN:[256..267] nonylphenol))
        (NP (-LRB-:[268..269] -LRB-) (NN:[269..271] NP) (-RRB-:[271..272] -RRB-))))
    (VP (VBD:[273..282] inhibited)
      (NP
        (NP
          (NML (JJ:[283..290] hepatic) (JJ:[291..301] microsomal)
            (NML
              (NML (NN:[303..320] 7-ethoxyresorufin)
                   (NN:[321..333] O-deethylase))
              (NML (-LRB-:[334..335] -LRB-) (NN:[335..339] EROD)
                   (-RRB-:[339..340] -RRB-))))
          (NN:[341..349] activity))
        (PP (IN:[350..352] of)
          (NP
            (ADJP (NN:[353..372] beta-naphthoflavone) (HYPH:[372..373] -)
                  (VBN:[373..380] treated))
            (NNS:[382..386] rats)))))
    (.:[386..387] .)))

;sentence 5 Span:388..667
;Enzyme kinetic analyses (Lineweaver-Burk plots) using different estradiol 
;and NP concentrations with graded increases in the concentrations of the 
;substrate, ethoxyresorufin, showed that the inhibition was of a competitive 
;nature at all concentrations of estradiol or NP used.
;[388..394]:substance:"Enzyme"
;[452..461]:substance:"estradiol"
;[467..469]:substance:"NP"
;[537..546]:substance:"substrate"
;[548..563]:substance:"ethoxyresorufin"
;[646..655]:substance:"estradiol"
;[659..661]:substance:"NP"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (NN:[388..394] Enzyme) (JJ:[395..402] kinetic)
            (NNS:[403..411] analyses))
        (PRN (-LRB-:[412..413] -LRB-)
          (NP
            (NML (NNP:[413..423] Lineweaver) (HYPH:[423..424] -)
                 (NNP:[424..428] Burk))
            (NNS:[429..434] plots))
          (-RRB-:[434..435] -RRB-)))
      (VP (VBG:[436..441] using)
        (NP (JJ:[442..451] different)
          (NML
            (NML (NN:[452..461] estradiol)
              (NML-1 (-NONE-:[461..461] *P*)))
            (CC:[463..466] and)
            (NML (NN:[467..469] NP)
              (NML-1 (NNS:[470..484] concentrations)))))
        (PP (IN:[485..489] with)
          (NP
            (NP (VBN:[490..496] graded) (NNS:[497..506] increases))
            (PP (IN:[507..509] in)
              (NP
                (NP (DT:[510..513] the) (NNS:[514..528] concentrations))
                (PP (IN:[529..531] of)
                  (NP
                    (NP (DT:[532..535] the) (NN:[537..546] substrate))
                    (,:[546..547] ,)
                    (NP (NN:[548..563] ethoxyresorufin))))))))))
    (,:[563..564] ,)
    (VP (VBD:[565..571] showed)
      (SBAR (IN:[572..576] that)
        (S
          (NP-SBJ (DT:[577..580] the) (NN:[581..591] inhibition))
          (VP (VBD:[592..595] was)
            (PP-PRD (IN:[596..598] of)
              (NP (DT:[599..600] a) (JJ:[601..612] competitive)
                  (NN:[614..620] nature)))
            (PP (IN:[621..623] at)
              (NP
                (NP (DT:[624..627] all) (NNS:[628..642] concentrations))
                (PP (IN:[643..645] of)
                  (NP
                    (NP (NN:[646..655] estradiol) (CC:[656..658] or)
                        (NN:[659..661] NP))
                    (VP (VBN:[662..666] used)
                      (NP (-NONE-:[666..666] *)))))))))))
    (.:[666..667] .)))

;sentence 6 Span:668..756
;Thus, the mechanism by  which NP inhibits EROD activity is similar to that of
;estradiol.
;[698..700]:substance:"NP"
;[710..714]:cyp450:"EROD"
;[746..755]:substance:"estradiol"
(SENT
  (S (RB:[668..672] Thus) (,:[672..673] ,)
    (NP-SBJ
      (NP (DT:[674..677] the) (NN:[678..687] mechanism))
      (SBAR
        (WHPP-1 (IN:[688..690] by)
          (WHNP (WDT:[692..697] which)))
        (S
          (NP-SBJ (NN:[698..700] NP))
          (VP (VBZ:[701..709] inhibits)
            (NP (NN:[710..714] EROD) (NN:[715..723] activity))
            (PP-1 (-NONE-:[723..723] *T*))))))
    (VP (VBZ:[724..726] is)
      (ADJP-PRD (JJ:[727..734] similar)
        (PP (TO:[735..737] to)
          (NP
            (NP (DT:[738..742] that))
            (PP (IN:[743..745] of)
              (NP (NN:[746..755] estradiol)))))))
    (.:[755..756] .)))

;sentence 7 Span:757..807
;NP, however,  was much less potent than estradiol.
;[757..759]:substance:"NP"
;[797..806]:substance:"estradiol"
(SENT
  (S
    (NP-SBJ (NN:[757..759] NP))
    (,:[759..760] ,)
    (ADVP (RB:[761..768] however))
    (VP (,:[768..769] ,) (VBD:[771..774] was)
      (ADJP-PRD
        (ADJP
          (ADVP (RB:[775..779] much) (RBR:[780..784] less))
          (JJ:[785..791] potent))
        (PP (IN:[792..796] than)
          (NP (NN:[797..806] estradiol)))))
    (.:[806..807] .)))

;sentence 8 Span:808..1014
;Young rats treated in vivo with 80 mg/kg  body weight of NP demonstrated a
;slight but significant decrease in their  hepatic microsomal EROD activity
;and CYP1A protein as measured by western blot  analysis.
;[840..842]:quantitative-value:"80"
;[843..861]:quantitative-units:"mg/kg  body weight"
;[865..867]:substance:"NP"
;[944..948]:cyp450:"EROD"
;[962..975]:cyp450:"CYP1A protein"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[808..813] Young) (NNS:[814..818] rats))
      (VP (VBN:[819..826] treated)
        (NP (-NONE-:[826..826] *))
        (ADVP (FW:[827..829] in) (FW:[830..834] vivo))
        (PP (IN:[835..839] with)
          (NP
            (NP (CD:[840..842] 80) (NN:[843..845] mg))
            (PP (SYM:[845..846] /)
              (NP
                (NP (NN:[846..848] kg))
                (NP (NN:[850..854] body) (NN:[855..861] weight))))
            (PP (IN:[862..864] of)
              (NP (NN:[865..867] NP)))))))
    (VP (VBD:[868..880] demonstrated)
      (NP
        (NP (DT:[881..882] a)
          (ADJP (JJ:[883..889] slight) (CC:[890..893] but)
                (JJ:[894..905] significant))
          (NN:[906..914] decrease))
        (PP-LOC (IN:[915..917] in)
          (NP (PRP$:[918..923] their)
            (NML
              (NML
                (NML (JJ:[925..932] hepatic) (JJ:[933..943] microsomal)
                     (NN:[944..948] EROD))
                (NN:[949..957] activity))
              (CC:[958..961] and)
              (NML (NN:[962..967] CYP1A) (NN:[968..975] protein))))))
      (SBAR (IN:[976..978] as)
        (S
          (NP-SBJ-1 (-NONE-:[978..978] *))
          (VP (VBN:[979..987] measured)
            (NP-1 (-NONE-:[987..987] *))
            (PP-MNR (IN:[988..990] by)
              (NP
                (NML (JJ:[991..998] western) (NN:[999..1003] blot))
                (NN:[1005..1013] analysis)))))))
    (.:[1013..1014] .)))

;sentence 9 Span:1015..1180
;In addition, treatment with NP led to a decrease in the steady-state  levels
;of hepatic CYP1A mRNA in rats, suggesting that NP acted at the 
;pre-translational level.
;[1043..1045]:substance:"NP"
;[1103..1113]:substance:"CYP1A mRNA"
;[1139..1141]:substance:"NP"
(SENT
  (S
    (PP (IN:[1015..1017] In)
      (NP (NN:[1018..1026] addition)))
    (,:[1026..1027] ,)
    (NP-SBJ
      (NP (NN:[1028..1037] treatment))
      (PP (IN:[1038..1042] with)
        (NP (NN:[1043..1045] NP))))
    (VP (VBD:[1046..1049] led)
      (PP-CLR (TO:[1050..1052] to)
        (NP
          (NP (DT:[1053..1054] a) (NN:[1055..1063] decrease))
          (PP (IN:[1064..1066] in)
            (NP
              (NP (DT:[1067..1070] the)
                (NML (JJ:[1071..1077] steady) (HYPH:[1077..1078] -)
                     (NN:[1078..1083] state))
                (NNS:[1085..1091] levels))
              (PP (IN:[1092..1094] of)
                (NP (JJ:[1095..1102] hepatic)
                   (NN:[1103..1108] CYP1A) (NN:[1109..1113] mRNA)))))
          (PP-LOC (IN:[1114..1116] in)
            (NP (NNS:[1117..1121] rats)))))
      (,:[1121..1122] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1122..1122] *))
        (VP (VBG:[1123..1133] suggesting)
          (SBAR (IN:[1134..1138] that)
            (S
              (NP-SBJ (NN:[1139..1141] NP))
              (VP (VBD:[1142..1147] acted)
                (PP (IN:[1148..1150] at)
                  (NP (DT:[1151..1154] the)
                    (ADJP (AFX:[1156..1159] pre) (HYPH:[1159..1160] -)
                          (JJ:[1160..1173] translational))
                    (NN:[1174..1179] level)))))))))
    (.:[1179..1180] .)))

;sentence 10 Span:1181..1345
;The competitive nature of inhibition by NP on hepatic  microsomal EROD
;activity indirectly suggests that this compound is a possible  substrate of
;the CYP1A enzyme.
;[1221..1223]:substance:"NP"
;[1247..1251]:cyp450:"EROD"
;[1291..1299]:substance:"compound"
;[1315..1324]:substance:"substrate"
;[1332..1344]:cyp450:"CYP1A enzyme"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1181..1184] The) (JJ:[1185..1196] competitive)
          (NN:[1197..1203] nature))
      (PP (IN:[1204..1206] of)
        (NP
          (NP (NN:[1207..1217] inhibition))
          (PP (IN:[1218..1220] by)
            (NP (NN:[1221..1223] NP)))))
      (PP (IN:[1224..1226] on)
        (NP
          (NML (JJ:[1227..1234] hepatic) (JJ:[1236..1246] microsomal)
               (NN:[1247..1251] EROD))
          (NN:[1252..1260] activity))))
    (ADVP (RB:[1261..1271] indirectly))
    (VP (VBZ:[1272..1280] suggests)
      (SBAR (IN:[1281..1285] that)
        (S
          (NP-SBJ (DT:[1286..1290] this) (NN:[1291..1299] compound))
          (VP (VBZ:[1300..1302] is)
            (NP-PRD
              (NP (DT:[1303..1304] a) (JJ:[1305..1313] possible)
                  (NN:[1315..1324] substrate))
              (PP (IN:[1325..1327] of)
                (NP (DT:[1328..1331] the)
                   (NN:[1332..1337] CYP1A) (NN:[1338..1344] enzyme))))))))
    (.:[1344..1345] .)))

;sentence 11 Span:1346..1436
;Furthermore, NP had a moderate modulating effect  on the expression of CYP1A
;in rat liver.
;[1359..1361]:substance:"NP"
;[1417..1422]:cyp450:"CYP1A"
(SENT
  (S
    (ADVP (RB:[1346..1357] Furthermore))
    (,:[1357..1358] ,)
    (NP-SBJ (NN:[1359..1361] NP))
    (VP (VBD:[1362..1365] had)
      (NP
        (NP (DT:[1366..1367] a) (JJ:[1368..1376] moderate)
            (VBG:[1377..1387] modulating) (NN:[1388..1394] effect))
        (PP (IN:[1396..1398] on)
          (NP
            (NP (DT:[1399..1402] the) (NN:[1403..1413] expression))
            (PP (IN:[1414..1416] of)
              (NP (NN:[1417..1422] CYP1A))))))
      (PP-LOC (IN:[1423..1425] in)
        (NP (NN:[1426..1429] rat) (NN:[1430..1435] liver))))
    (.:[1435..1436] .)))

;section 12 Span:1440..1484
;PMID: 8781507 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1440..1444] PMID) (::[1444..1445] :) (CD:[1446..1453] 8781507)
        (-LRB-:[1454..1455] -LSB-) (NNP:[1455..1461] PubMed)
        (HYPH:[1462..1463] -) (NN:[1464..1471] indexed) (IN:[1472..1475] for)
        (NNP:[1476..1483] MEDLINE) (-RRB-:[1483..1484] -RSB-)))
